Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.
A jet collided with an Army helicopter while approaching the Ronald Reagan National Airport near Washington. Here are some things to know about the collision.
CreditAccess Grameen's shares have surged by nearly 17% over four trading sessions despite a sequential decline in loan disbursements and a net loss due to increased provisioning. The company has forecasted recovery in operating parameters starting from the March quarter, with improved business momentum and risk management.
